Ken Griffin Guardant Health, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Guardant Health, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 90,800 shares of GH stock, worth $2.87 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

90,800

Previous 66,200 37.16%

Holding current value

$2.87 Million

Previous $1.91 Million 8.95%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$22.3 - $36.29 $66 Million - $107 Million	-2,960,496 Reduced 89.96%	330,401 $7.58 Million
Q2 2024 Aug 14, 2024	BUY	$16.07 - $31.84 $8.04 Million - $15.9 Million	500,359 Added 17.93%	3,290,897 $95 Million
Q1 2024 May 15, 2024	BUY	$17.13 - $26.91 $47.3 Million - $74.3 Million	2,762,668 Added 9912.69%	2,790,538 $57.6 Million
Q4 2023 Feb 14, 2024	SELL	$21.58 - $29.5 $8.86 Million - $12.1 Million	-410,445 Reduced 93.64%	27,870 $753,000
Q3 2023 Nov 14, 2023	BUY	$25.8 - $39.97 $733,184 - $1.14 Million	28,418 Added 6.93%	438,315 $13 Million
Q2 2023 Aug 14, 2023	BUY	$20.94 - $38.01 $2.99 Million - $5.43 Million	142,831 Added 53.48%	409,897 $14.7 Million
Q1 2023 May 15, 2023	SELL	$22.92 - $33.76 $379,830 - $559,470	-16,572 Reduced 5.84%	267,066 $6.26 Million
Q4 2022 Feb 14, 2023	SELL	$25.44 - $59.78 $1.74 Million - $4.08 Million	-68,214 Reduced 19.39%	283,638 $7.71 Million
Q3 2022 Nov 14, 2022	BUY	$43.66 - $61.0 $9.43 Million - $13.2 Million	216,050 Added 159.09%	351,852 $18.9 Million
Q2 2022 Aug 15, 2022	SELL	$28.82 - $77.35 $11.5 Million - $30.8 Million	-398,623 Reduced 74.59%	135,802 $5.48 Million
Q1 2022 May 16, 2022	BUY	$48.25 - $100.49 $707,779 - $1.47 Million	14,669 Added 2.82%	534,425 $35.4 Million
Q4 2021 Feb 14, 2022	BUY	$88.71 - $120.43 $31.3 Million - $42.5 Million	353,092 Added 211.86%	519,756 $52 Million
Q2 2021 Aug 16, 2021	SELL	$109.77 - $165.68 $8.77 Million - $13.2 Million	-79,867 Reduced 32.4%	166,664 $20.7 Million
Q1 2021 May 17, 2021	SELL	$127.04 - $179.1 $4.87 Million - $6.87 Million	-38,356 Reduced 13.46%	246,531 $37.6 Million
Q4 2020 Feb 16, 2021	BUY	$99.96 - $135.93 $4.43 Million - $6.03 Million	44,351 Added 18.44%	284,887 $36.7 Million
Q3 2020 Nov 16, 2020	BUY	$80.32 - $111.8 $14.3 Million - $19.9 Million	178,206 Added 285.91%	240,536 $26.9 Million
Q2 2020 Aug 14, 2020	SELL	$60.49 - $97.5 $3.89 Million - $6.28 Million	-64,367 Reduced 50.8%	62,330 $5.06 Million
Q1 2020 May 15, 2020	BUY	$59.04 - $88.81 $4.83 Million - $7.27 Million	81,876 Added 182.67%	126,697 $8.82 Million
Q4 2019 Feb 14, 2020	SELL	$59.49 - $82.78 $4.64 Million - $6.46 Million	-78,024 Reduced 63.51%	44,821 $3.5 Million
Q3 2019 Nov 14, 2019	BUY	$62.59 - $110.3 $2.86 Million - $5.05 Million	45,771 Added 59.39%	122,845 $7.84 Million
Q2 2019 Aug 14, 2019	SELL	$63.94 - $91.11 $981,351 - $1.4 Million	-15,348 Reduced 16.61%	77,074 $6.65 Million
Q1 2019 May 15, 2019	BUY	$34.3 - $97.98 $3.17 Million - $9.06 Million	92,422 New	92,422 $0

Others Institutions Holding GH

# of Institutions

323

Shares Held

127M

Call Options Held

844K

Put Options Held

2.38M

View Full List

About Guardant Health, Inc.

Ticker GH
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 102,220,000
Market Cap $3.23B
Description
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a cl...

More about GH

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account